JP2023036899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023036899A5 JP2023036899A5 JP2022211496A JP2022211496A JP2023036899A5 JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5 JP 2022211496 A JP2022211496 A JP 2022211496A JP 2022211496 A JP2022211496 A JP 2022211496A JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- antibody
- pharmaceutical composition
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218361A JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455245P | 2017-02-06 | 2017-02-06 | |
| US62/455,245 | 2017-02-06 | ||
| PCT/US2018/017027 WO2018145075A1 (en) | 2017-02-06 | 2018-02-06 | Compositions and methods for augmenting antibody mediated receptor signaling |
| JP2019542388A JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Division JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218361A Division JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023036899A JP2023036899A (ja) | 2023-03-14 |
| JP2023036899A5 true JP2023036899A5 (enExample) | 2023-10-03 |
| JP7606501B2 JP7606501B2 (ja) | 2024-12-25 |
Family
ID=63040120
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Active JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2022211496A Active JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Active JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220213206A1 (enExample) |
| EP (1) | EP3576793A4 (enExample) |
| JP (3) | JP7231549B2 (enExample) |
| CN (1) | CN110520158A (enExample) |
| AU (2) | AU2018215673B2 (enExample) |
| CA (1) | CA3049689A1 (enExample) |
| WO (1) | WO2018145075A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001262A2 (pt) * | 2016-07-22 | 2019-05-07 | Dana-Farber Cancer Institute, Inc. | anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| RU2734432C1 (ru) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| US20240239905A1 (en) * | 2021-05-13 | 2024-07-18 | Arizona Board Of Regents On Behalf Of Arizona State University | A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| AU2023324669A1 (en) | 2022-08-15 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| EP4572785A1 (en) | 2022-08-15 | 2025-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912224A (en) * | 1996-02-22 | 1999-06-15 | The General Hospital Corporation | Methods and compositions for enhancing cellular response to TGF-β ligands |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| AU2015200990B2 (en) * | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| KR20200024345A (ko) * | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| WO2014122143A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| MA40609B1 (fr) * | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| DK3215528T3 (da) * | 2014-11-06 | 2019-10-07 | Hoffmann La Roche | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder |
| AU2016227632A1 (en) * | 2015-03-05 | 2017-09-14 | Ucb Biopharma Sprl | Polymeric Fc proteins and methods of screening to alter their functional characteristics |
| KR20180002653A (ko) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| CN120795163A (zh) * | 2016-10-14 | 2025-10-17 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| US20190276549A1 (en) * | 2016-11-01 | 2019-09-12 | Genmab B.V. | Polypeptide variants and uses thereof |
-
2018
- 2018-02-06 EP EP18748152.8A patent/EP3576793A4/en active Pending
- 2018-02-06 JP JP2019542388A patent/JP7231549B2/ja active Active
- 2018-02-06 US US16/483,738 patent/US20220213206A1/en not_active Abandoned
- 2018-02-06 AU AU2018215673A patent/AU2018215673B2/en active Active
- 2018-02-06 CA CA3049689A patent/CA3049689A1/en not_active Abandoned
- 2018-02-06 CN CN201880010285.3A patent/CN110520158A/zh active Pending
- 2018-02-06 WO PCT/US2018/017027 patent/WO2018145075A1/en not_active Ceased
-
2022
- 2022-12-28 JP JP2022211496A patent/JP7606501B2/ja active Active
-
2023
- 2023-12-04 US US18/528,382 patent/US20240336694A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218361A patent/JP2025028191A/ja active Pending
-
2025
- 2025-04-22 AU AU2025202811A patent/AU2025202811A1/en active Pending